The role of 131I-MIBG in high-risk neuroblastoma treatment

Journal of Pediatric Oncology Nursing

Volumn 26, Issue 4, 2009, Pages 208-216

  Lessig, Megan Kinnear ^a  

^a CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

Author keywords

131I MIBG; Neuroblastoma; Nursing; Radiation; Treatment

Indexed keywords

(3 IODOBENZYL)GUANIDINE; ANTINEOPLASTIC AGENT; MYCN PROTEIN, HUMAN; NUCLEAR PROTEIN; ONCOPROTEIN; RADIOACTIVE IODINE;

CANCER STAGING; CHILD; HUMAN; MULTIMODALITY CANCER THERAPY; NEUROBLASTOMA; PATHOLOGY; PRESCHOOL CHILD; REVIEW; RISK ASSESSMENT;

3-IODOBENZYLGUANIDINE; ANTINEOPLASTIC AGENTS; CHILD; CHILD, PRESCHOOL; COMBINED MODALITY THERAPY; HUMANS; IODINE RADIOISOTOPES; NEOPLASM STAGING; NEUROBLASTOMA; NUCLEAR PROTEINS; ONCOGENE PROTEINS; RISK ASSESSMENT;

EID: 70349316153     PISSN: 10434542     EISSN: 15328457     Source Type: Journal    
DOI: 10.1177/1043454209340316     Document Type: Article

References (21)

1. Bailey, H.H., Mulcahy, R.T., Tutsch, K.D., Arzoomanian, R.Z., Alberti, D., Tombes, M.B., et al. (1994). Phase I clinical trial of intravenous 1-buthione sulfoxime and melphalan: An attempt at modulation of glutathione. Journal of Clinical Oncology, 12, 194-205.
2. Brodeur, G.M., Pritchard, J., Berthold, F., Carlsen, N.L.T., Castel, V., Castleberry, R.P., et al. (1993). Revisions of international criteria for neuroblastoma diagnosis, staging, and response to treatment. Journal of Clinical Oncology, 11, 1466-1477.
3. 131I-MIBG as a targeted radiotherapeutic for children with neuroblastoma. Unpublished manuscript.
4. Brophy, P., Schmus, C., & Balistreri, L. (2004). Meeting the nursing challenges in treating children with 131I-MIBG. Journal of Pediatric Oncology Nursing, 21, 9-15.
5. Dadd, G. (2002). Neuroblastoma. In C. R. Baggott, K. P. Kelly, D. Fochtman, & G. V. Foley (Eds.), Nursing care of children and adolescents with cancer (pp. 545-554). Philadelphia: W. B. Saunders.
6. De Kraker, J., Hoefnagel, K.A., Verschuur, A.C., van Eck, B., van Santen, H.M., & Caron, H.N. (2008). Iodine-131-metaiodobenzylguanidine as initial induction therapy in stage 4 neuroblastoma patients over 1 year of age. European Journal of Cancer, 44, 551-556.
7. Goldsby, R.E., & Matthay, K.K. (2004). Neuroblastoma: Evolving therapies for a disease with many faces. Pediatric Drugs, 6, 107-122.
8. Howard, J.P., Maris, J.M., Kersun, L.S., Huberty, J.P., Cheng, S.C., Hawkins, R.A., et al. (2005). Tumor response and toxicity with multiple infusions of high dose 131I-MIBG for refractory neuroblastoma. Pediatric Blood Cancer, 44, 232-239.
9. Kang, T.I., Brophy, P., Hickeson, M., Heyman, S., Evans, A.E., Charron, M., et al. (2003). Targeted radiotherapy with submyeloblative doses of 131I-MIBG is effective for disease palliation in highly refractory neuroblastoma. Journal of Pediatric Hematology Oncology, 25, 769-773.
10. Katzenstein, H.M., & Cohn, S.L. (1998). Advances in diagnosis and treatment of neuroblastoma. Current Opinion in Oncology, 10, 43-51.
11. Kushner, B.H., Cheung, N.K.V., Kramer, K., Dunkel, I.J., Calleja, E., & Boulad, F. (2001). Topotecan combined with myeloablative doses of thiotepa and carboplatin for neuroblastoma, brain tumors, and other poor risk solid tumors in children and young adults. Bone Marrow Transplantation, 28, 551-556.
12. Maris, J.M., Hogarty, M.D., Bagatell, R., & Cohn, S.L. (2007). Neuroblastoma. Lancet, 369, 2106-2120.
13. Mastrangelo, S., Tornesello, A., Diociaiuti, L., Pession, A., Prete, A., Rufini, V., et al. (2001). Treatment of advanced neuroblastoma: Feasibility and therapeutic potential of a novel approach combining 131-I-MIBG and multiple drug therapy. British Journal of Cancer, 84, 460-464.
14. Matthay, K.K., Tan, J.C., Villablanca, J.G., Yanik, G.A., Veatch, J., Franc, B., et al. (2006). Phase I dose escalation of iodine-131-metaiodobenzylguanidine with myeloablative chemotherapy and autologous stem-cell transplantation in refractory neuroblastoma: A new approaches to neuroblastoma therapy consortium study. Journal of Clinical Oncology, 24, 500-506.
15. Matthay, K.K., Yanik, G., Messina, J., Quach, A., Huberty, J., Cheng, S.C., et al. (2007). Phase II study on the effect of disease sites, age, and prior therapy on response to iodine-131-metaiodobenzylguanidine therapy in refractory neuroblastoma. Journal of Clinical Oncology, 25, 1054-1060.
16. 131I]MIBG and topotecan: A rationale for combination therapy for neuroblastoma. Cancer Letters, 228, 221-227.
17. Miano, M., Garaventa, A., Pizzitola, M.R., Lo Piccolo, M.S., Dallorso, S., Villavecchia, G.P., et al. (2001). Megatherapy combining I131 metaiodobenzylguadidine and high-dose chemotherapy with haematopoietic progenitor cell rescue for neuroblastoma. Bone Marrow Transplantation, 27, 571-574.
18. Pashankar, F.D., O'Dorisio, M.S., & Menda, Y. (2005). MIBG and somatostatin receptor analogs in children: Current concepts on diagnostic and therapeutic use. Journal of Nuclear Medicine, 46, 55S-61S.
19. Saylors, R.L., Stine, K.C., Sullivan, J., Kepner, J.L., Wall, D.A., Bernstein, M.L., et al. (2001). Cyclophosphamide plus topotecan in children with recurrent or refractory solid tumors: A pediatric oncology group phase II study. Journal of Clinical Oncology, 19, 3463-3469.
20. 131I-MIBG therapy in neuroblastoma: Mechanisms, rationale, and current status. Medical and Pediatric Oncology, 32, 427-431.
21. van Santen, H.M., de Kraker, J., van Eck, B.L.F., de Vijler, J.J.M., & Vulsma, T. (2003). Improved radiation protection of the thyroid gland with thyroxine, methimazole, and potassium iodide during diagnostic and therapeutic use of radiolabeled metaiodobenzylguanidine in children with neuroblastoma. Cancer, 98, 389-396.